

Table of Contents

State/Territory Name: Virginia

State Plan Amendment (SPA)#: VA-25-0021

This file contains the following documents in the order listed

- 1) Approval Letter
- 2) CMS 179 Form
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop S2-14-26
Baltimore, Maryland 21244-1850



Center for Medicaid and CHIP Services

Medical Benefits Health Programs Group

October 27, 2025

Cheryl J. Roberts, Director
Department of Medical Assistance Services
600 East Broad Street, Suite 1300
Richmond, VA 23219

Dear Cheryl J. Roberts,

The CMS Division of Pharmacy team has reviewed Virginia State Plan Amendment (SPA) 25-0021 received in the CMS Medicaid Services OneMAC application on September 18, 2025. This SPA proposes to revise the number of members needed for a quorum for action of the P&T Committee.

Based on the information provided and consistent with the regulations at 42 CFR 430.20, we are pleased to inform you that SPA 25-0021 is approved with an effective date of July 1, 2025. Our review was limited to the materials necessary to evaluate the SPA under applicable federal laws and regulations.

We are attaching a copy of the signed CMS-179 form, as well as the page approved for incorporation into Virginia's state plan. If you have any questions regarding this amendment, please contact Porscha Brink at (202) 260-4025 or Porscha.brink@cms.hhs.gov.

Sincerely,

Catherine A. Traugott, R.Ph., J.D.
Acting Director
Division of Pharmacy

cc: Meredith Lee, Policy, Regulations, & Manuals Supervisor, DMAS
Margaret Kosherzenko, VA State Lead, Medicaid and CHIP Operations Group, CMS

**TRANSMITTAL AND NOTICE OF APPROVAL OF
STATE PLAN MATERIAL
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES**

1. TRANSMITTAL NUMBER

2. STATE

3. PROGRAM IDENTIFICATION: TITLE OF THE SOCIAL
SECURITY ACT XIX XXI

TO: CENTER DIRECTOR
CENTERS FOR MEDICAID & CHIP SERVICES
DEPARTMENT OF HEALTH AND HUMAN SERVICES

4. PROPOSED EFFECTIVE DATE

5. FEDERAL STATUTE/REGULATION CITATION

6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars)
a. FFY _____ \$ _____
b. FFY _____ \$ _____

7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT

8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION
OR ATTACHMENT (*If Applicable*)

9. SUBJECT OF AMENDMENT

10. GOVERNOR'S REVIEW (*Check One*)

GOVERNOR'S OFFICE REPORTED NO COMMENT
COMMENTS OF GOVERNOR'S OFFICE ENCLOSED
NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL

OTHER, AS SPECIFIED:
Secretary of Health and Human Resources

11. SIGNATURE OF STATE AGENCY OFFICIAL

15. RETURN TO

12. TYPED NAME

13. TITLE

14. DATE SUBMITTED

FOR CMS USE ONLY

16. DATE RECEIVED

September 18, 2025

17. DATE APPROVED

October 27, 2025

PLAN APPROVED - ONE COPY ATTACHED

18. EFFECTIVE DATE OF APPROVED MATERIAL

July 1, 2025

19. SIGNATURE OF APPROVING OFFICIAL

20. TYPED NAME OF APPROVING OFFICIAL

Catherine A. Traugott, R.Ph., J.D.

21. TITLE OF APPROVING OFFICIAL

Acting Director, Division of Pharmacy

22. REMARKS

August, 1991

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT

State of VIRGINIA

**AMOUNT, DURATION, AND SCOPE OF MEDICAL
AND REMEDIAL CARE AND SERVICES PROVIDED TO THE CATEGORICALLY NEEDY
and MEDICALLY NEEDY**

- b. Medicaid Pharmacy and Therapeutics Committee.
- (1) The Department shall utilize a Pharmacy and Therapeutics Committee (the "P & T Committee") to assist in the development and ongoing administration of the preferred drug list and other pharmacy program issues. The Committee may adopt bylaws that set out its make-up and functioning. A quorum for action of the Committee shall consist of nine members.
 - (2) Vacancies on the Committee shall be filled in the same manner as original appointments. The Department shall appoint individuals for the Committee that assures a cross-section of the physician and pharmacy community.
 - (3) Duties of the Committee. The Committee shall receive and review clinical and pricing data related to the drug classes. The Committee's medical and pharmacy experts shall make recommendations to DMAS regarding various aspects of the pharmacy program. For the preferred drug list program, the Committee shall select those drugs to be deemed preferred that are safe, clinically effective, as supported by available clinical data, and meet pricing standards. Cost-effectiveness or any pricing standard shall be considered only after a drug is determined to be safe and clinically effective.
 - (4) As the United States Food and Drug Administration (FDA) approves new drug products, the Department shall ensure that the Pharmacy and Therapeutics Committee will evaluate the drug for clinical appropriateness. Based on clinical information and pricing standards, the P&T Committee will determine if the drug will be included in the PDL or require prior authorization.

TN No. 25-0021Approval Date 10-27-25Effective Date 07-01-25

Supersedes

TN No. 05-02